The Stars of Tomorrow are the Young Investigators of Today!

Bakes for Breast Cancer will now be funding the up and coming research of young investigators in breast cancer research.  Our Medical Advisory Board will direct the best use of our funds raised in the support of the young investigators.

Funds raised in 2019 and 2020 will support the research of Dr. Rachel Freedman.

Rachel Freedman, M.D.

Dr. Rachel Freedman is a medical oncologist specializing in breast cancer at Dana-Farber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School, and Medical Director of the Dana-Farber Cancer Care Collaborative. Her research primarily focuses on the care of vulnerable patients populations who are not well represented in clinical trials to date and who suffer from worse outcomes once they are diagnosed with breast cancer. Her research has included large scale database and registry-based studies, focus group studies, survey studies, and interventions targeted towards improving the evidence base and outcomes for women at risk for poor outcomes.

We will be supporting Dr. Freedman’s research in older women with breast cancer.  Although breast cancer is more common in aging populations, older women with breast cancer are under-represented in research, are more likely be under-treated, and are at higher risk for worse survival from their breast cancer compared with middle-aged women.

Dr. Freedman is a graduate of Georgetown University School of Medicine.  She completed her residency at Beth Israel Medical Center and her medical oncology fellowship at Dana-Farber Cancer Institute. She received a Masters in Public Health from Harvard University’s School of Public Health and has been on faculty at Dana-Farber since 2009.

Funds raised in 2017 and 2018 will support the research of Dr. Shom Goel.

Dr. Shom Goel

Dr Shom Goel is a breast cancer oncologist who is also a physician-scientist.  He divides his time between the laboratory bench and the patient’s bedside. This year we will be finding his research that addresses the important question “Why are some breast cancers resistant to the drug treatments we use in the clinic?” His laboratory research is often inspired by his experiences with patients. Because Dr. Goel is also a clinician, he has the potential to take promising new treatments he develops in the laboratory and move them forward in clinical trials. His current work is focused on understanding how breast cancers are able to “hide” from the immune system and relates to the fast-growing field of cancer immunotherapy.

Dr. Goel graduated from the University of Adelaide Medical School and completed medical oncology training in Sydney.  Dr. Shom Goel works at Harvard Medical School and Dana-Farber Cancer Institute in Boston Massachusetts.

Funds raised in 2015 and 2016 will benefit the research of Heather A. Parsons, MD, MPH

Parsons Bio Photo

Heather A. Parsons, MD, MPH

Heather A. Parsons, MD, MPH is a medical oncologist at Dana-Farber Cancer Institute (DFCI) and Instructor of Medicine at Harvard Medical School. Dr. Parsons’ research focuses on breast cancer and the use of blood-based genomic biomarkers to understand the course of a woman’s breast cancer and response to treatment. Ultimately, she aims to develop these biomarkers to better direct existing treatments, to avoid overtreatment, and to develop new treatments to help patients live better, longer lives.

Dr. Parsons is a graduate of Dartmouth College and has a Master in Public Health from Johns Hopkins Bloomberg School of Public Health. She received her medical degree from Drexel University College of Medicine, followed by internship and residency in Internal Medicine at Johns Hopkins Hospital. She then completed a fellowship in Medical Oncology at Johns Hopkins Hospital before joining the faculty at Dana-Farber Cancer Institute. Dr. Parsons’ honors and awards include a Young Investigator Award from the American Society of Clinical Oncology. She is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and the Translational Breast Cancer Research Consortium.